Targeting LIN28: a new hope in prostate cancer theranostics

Shrivastava, G; Aljabali, AAA; Shahcheraghi, SH; Lotfi, M; Shastri, MD; Shukla, SD; Chellappan, DK; Jha, NK; Anand, K; Dureja, H; Pabari, RM; Mishra, V; Almutary, AG; Alnuqaydan, AM; Charbe, N; Prasher, P; Negi, P; Goyal, R; Dua, K; Gupta, G; Serrano-Aroca, Á; Bahar, B; Barh, D; Panda, PK; Takayama, K; Lundstorm, K; McCarron, P; Bakshi, H; Tambuwala, MM

Targeting LIN28: a new hope in prostate cancer theranostics

Shrivastava, G Aljabali, AAA Shahcheraghi, SH Lotfi, M Shastri, MD Shukla, SD Chellappan, DK Jha, NK Anand, K Dureja, H Pabari, RM Mishra, V Almutary, AG Alnuqaydan, AM Charbe, N Prasher, P Negi, P Goyal, R Dua, K

Gupta, G Serrano-Aroca, Á Bahar, B Barh, D Panda, PK Takayama, K Lundstorm, K McCarron, P Bakshi, H Tambuwala, MM

Permalink

Publisher:: Future Medicine Ltd
Publication Type:: Journal Article
Citation:: Future Oncology

Closed Access

	Filename	Description	Size
	LIN 28_Cancer theranostics_fon-2021-0247.pdf	Published version	3.22 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shrivastava, G
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Shahcheraghi, SH
dc.contributor.author	Lotfi, M
dc.contributor.author	Shastri, MD
dc.contributor.author	Shukla, SD
dc.contributor.author	Chellappan, DK
dc.contributor.author	Jha, NK
dc.contributor.author	Anand, K
dc.contributor.author	Dureja, H
dc.contributor.author	Pabari, RM
dc.contributor.author	Mishra, V
dc.contributor.author	Almutary, AG
dc.contributor.author	Alnuqaydan, AM
dc.contributor.author	Charbe, N
dc.contributor.author	Prasher, P
dc.contributor.author	Negi, P
dc.contributor.author	Goyal, R
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Gupta, G
dc.contributor.author	Serrano-Aroca, Á
dc.contributor.author	Bahar, B
dc.contributor.author	Barh, D
dc.contributor.author	Panda, PK
dc.contributor.author	Takayama, K
dc.contributor.author	Lundstorm, K
dc.contributor.author	McCarron, P
dc.contributor.author	Bakshi, H
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2021-07-15T23:23:38Z
dc.date.available	2021-07-15T23:23:38Z
dc.identifier.citation	Future Oncology
dc.identifier.issn	1479-6694
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/10453/149883
dc.description.abstract	<jats:p> The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area. </jats:p>
dc.language	en
dc.publisher	Future Medicine Ltd
dc.relation.ispartof	Future Oncology
dc.relation.isbasedon	10.2217/fon-2021-0247
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Targeting LIN28: a new hope in prostate cancer theranostics
dc.type	Journal Article
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2021-07-15T23:23:36Z
pubs.publication-status	Published online

Abstract:

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149883